Deciphera Pharmaceuticals Inc Stock News

Blueprint Medicines Corp (NASDAQ: BPMC) shares were taking a beating Tuesday after the company announced a negative late-stage readout for its lead asset avapritinib in...

In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Deciphera Pharmaceuticals (DCPH). The company's shares closed last

In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Deciphera Pharmaceuticals (DCPH – Research Report).

Broadwind Energy (NASDAQ:BWEN) +60%. on $19M order.TrovaGene (NASDAQ:TROV) +44% on new positive results from its ongoing Phase 1b/2 clinical trial of onvansertib in combination with FOLFIRI and Avast

Deciphera Pharmaceuticals (NASDAQ:DCPH) is up 16% premarket on light volume on the heels on Blueprint Medicines' plunge after announcing unsuccessful results from late-stage study of avapritinib in�

Blueprint Medicines (NASDAQ:BPMC) slumps 15% premarket in reaction to its announcement that a Phase 3 clinical trial, VOYAGER, evaluating lead candidate avapritinib, branded as Ayvakit, in patients

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it will report its first q

Des envois postaux  réduits à la portion congrue , personne dans les bureaux pour ouvrir le courrier et récupérer les factures ou les...

Looking for the perfect coffee maker for your favorite brews? From simple to complex, you'll find the most efficient and smartest models available on our list.

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) traded up 5.6% during mid-day trading on Friday . The stock traded as high as $48.45 and last traded at $48.02, 392,227 shares changed hands during mid-day

Deciphera Pharmaceuticals (DCPH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Deciphera Pharmaceuticals (DCPH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Director Michael Douglas Taylor sold 23,892 shares of the business’s stock in a transaction on Friday, April 17th. The shares were sold at an average pric

What should investors think of this late-stage cancer biotech?

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Director Michael Douglas Taylor sold 1,108 shares of the business’s stock in a transaction dated Tuesday, April 14th. The shares were sold at an average p